Bioscience Association Manitoba (BAM) is pleased to host its Annual Awards Dinner, ‘Bridging Innovative Opportunities in Manitoba’ on March 7, 2024, to celebrate the accomplishments and future potential of the bioscience industry in Manitoba.
ImmunoFyx is a private early-stage biotechnology company focused on novel antibody fusion proteins targeting highly metastatic solid tumours. Up to 90% of cancer deaths are associated with metastases for which there are few treatment options. ImmunoFyx utilizes unique combinations of endogenous anti-cancer proteins to reduce tumour growth, angiogenesis and metastases.
Contact InfoWinnipeg MB